Literature DB >> 17334745

[Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks].

A Lommatzsch1, G Spital, M Trieschmann, D Pauleikhoff.   

Abstract

Angioid streaks are the typical ophthalmological manifestation of the systemic disease pseudoxanthoma elasiticum. Fundoscopy reveals angioid streaks as irregular dark brownish lines radiating from the area around the optic disc. Choroidal neovascularization (CNV) is the major cause of severe visual loss in patients with angioid streaks. Argon-laser treatment of CNV secondary to angioid streaks shows poor results. Photodynamic therapy (PDT) with verteporfin does not seem to be an effective treatment for achieving stabilization of visual acuity and lesion size in CNV secondary to angioid streaks. Results after a combination of the intravitreal application of triamcinolone with PDT did not show the expected benefit. In the era of promising new intravitreal treatments for patients suffering from age-related macular degeneration, it is interesting to observe this effect of angiogenesis inhibitors (bevacizumab, ranibizumab, pegaptanib) in patients with neovascilarization secondary to angioid streaks. In our case, we observed a deterioration in visual acuity and leakage of the CNV after treatment with PDT alone. However, after the intravitreal injection of bevacizumab, we observed an improvement in vision, and the area of neovascularization changed into a fibrotic scar. A controlled study with long-term results is needed to definitively evaluate this kind of treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17334745     DOI: 10.1007/s00347-006-1456-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  12 in total

1.  Therapeutic strategies in choroidal neovascularizations secondary to angioid streaks.

Authors:  Stefan Mennel; Jörg C Schmidt; Carsten H Meyer
Journal:  Am J Ophthalmol       Date:  2003-09       Impact factor: 5.258

Review 2.  [Pseudoxanthoma elasticum].

Authors:  M S Ladewig; C Götting; C Szliska; P C Issa; H-M Helb; I Bedenicki; H P N Scholl; F G Holz
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

3.  [Introduction to the topic: Off-label use of bevacizumab in the treatment of neovascular age-related macular degeneration].

Authors:  K U Bartz-Schmidt; F G Holz
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

4.  Photodynamic therapy using verteporfin for choroidal neovascularization associated with angioid streaks--long-term effects.

Authors:  Bernhard Jurklies; Norbert Bornfeld; Harald Schilling
Journal:  Ophthalmic Res       Date:  2006-05-04       Impact factor: 2.892

5.  Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization.

Authors:  Richard F Spaide; John Sorenson; Leandro Maranan
Journal:  Retina       Date:  2005-09       Impact factor: 4.256

Review 6.  [(Side) effects of VEGF inhibition].

Authors:  F Ziemssen; K U Bartz-Schmidt; S Grisanti
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

Review 7.  [Intravitreal bevacizumab for neovascular age-related macular degeneration].

Authors:  M S Ladewig; F Ziemssen; G Jaissle; H-M Helb; H P N Scholl; N Eter; K U Bartz-Schmidt; F G Holz
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

8.  Photodynamic therapy with verteporfin for choroidal neovascularization associated with angioid streaks.

Authors:  Heinrich Heimann; Faik Gelisken; Joachim Wachtlin; Andreas Wehner; Michael Völker; Michael H Foerster; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-10       Impact factor: 3.117

9.  Outcome of choroidal neovascularization in angioid streaks after photodynamic therapy.

Authors:  Ugo Menchini; Gianni Virgili; Ugo Introini; Francesco Bandello; Massimo Ambesi-Impiombato; Alfredo Pece; Maurizio Battaglia Parodi; Giovanni Giacomelli; Benedetta Capobianco; Monica Varano; Rosario Brancato
Journal:  Retina       Date:  2004-10       Impact factor: 4.256

10.  Visual results after surgical removal of subfoveal choroidal neovascular membranes.

Authors:  M A Thomas; J D Dickinson; N S Melberg; H E Ibanez; R S Dhaliwal
Journal:  Ophthalmology       Date:  1994-08       Impact factor: 12.079

View more
  7 in total

1.  Choroidal neovascularization and angioid streaks in pseudoxanthoma elasticum.

Authors:  Melisa Nika; Cagri G Besirli
Journal:  Int J Ophthalmol       Date:  2011-08-18       Impact factor: 1.779

2.  Verteporfin photodynamic therapy combined with intravitreal triamcinolone for choroidal neovascularization due to angioid streaks.

Authors:  Alfredo Pece; Gaetano Russo; Federico Ricci; Vincenzo Isola; Ugo Introini; Giuseppe Querques
Journal:  Clin Ophthalmol       Date:  2010-06-24

3.  [Intraocular injections of bevacizumab in rare indications--two cases].

Authors:  T Wecke; C Knop; W Schreiber; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

4.  Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum.

Authors:  Martin Ganssauge; Helmut Wilhelm; Karl-Ulrich Bartz-Schmidt; Sabine Aisenbrey
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12       Impact factor: 3.117

Review 5.  Bevacizumab: off-label use in ophthalmology.

Authors:  Salvatore Grisanti; Focke Ziemssen
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

6.  Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania.

Authors:  Horia T Stanca; Simona Stanca; Bogdana Tabacaru; Madalina Boruga; Florian Balta
Journal:  Exp Ther Med       Date:  2019-08-06       Impact factor: 2.447

Review 7.  Therapy of Pseudoxanthoma Elasticum: Current Knowledge and Future Perspectives.

Authors:  Max Jonathan Stumpf; Nadjib Schahab; Georg Nickenig; Dirk Skowasch; Christian Alexander Schaefer
Journal:  Biomedicines       Date:  2021-12-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.